PAI
NKTR icon

Pittenger & Anderson Inc’s Nektar Therapeutics NKTR Stock Holding History

Pittenger & Anderson Inc’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20
Closed -$18K – 390
2017
Q4 		$18K Buy
+20
New +$11.8K ﹤0.01% 326

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pittenger & Anderson Inc's NKTR Position: Q1 2018 in Review

Pittenger & Anderson Inc sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 20 shares — an estimated $18K sold.

Pittenger & Anderson Inc first reported a position in NKTR in Q4 2017 and held it in 1 quarter. The position peaked at $18K in Q4 2017. 359 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Pittenger & Anderson Inc reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 20 Nektar Therapeutics shares in Q1 2018, an estimated $18K.
  • Pittenger & Anderson Inc first reported a position in Nektar Therapeutics in Q4 2017 and held it in 1 quarter.
  • Pittenger & Anderson Inc's Nektar Therapeutics position peaked at $18K in Q4 2017.
  • 359 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2018, filed 8 May 2018.